Friday, August 23, 2019 3:30:05 PM
Recent SLRX News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 12:11:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 12:05:28 PM
- Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:04:58 PM
- Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split • GlobeNewswire Inc. • 06/12/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:17:10 PM
- Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/22/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:29:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:25:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:13:07 PM
- Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:04:46 PM
- Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/27/2023 07:57:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 09:09:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:14:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:13:50 PM
- Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 08/10/2023 08:05:00 PM
- Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources • GlobeNewswire Inc. • 08/08/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2023 01:22:11 PM
- Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients • GlobeNewswire Inc. • 07/11/2023 12:30:00 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM